Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study.

Zambrano DA, Lintis A, Kefleyesus A, Taibi A, Eveno C, Pocard M, De Meeus G, Quénet F, Kepenekian V, Hübner M, Glehen O, Sgarbura O

Open source

DOI: 10.1016/j.ejso.2026.111731
Published: 2026 May
Container: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejso.2026.111731,
  title = {Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study.},
  author = {Zambrano DA and Lintis A and Kefleyesus A and Taibi A and Eveno C and Pocard M and De Meeus G and Quénet F and Kepenekian V and Hübner M and Glehen O and Sgarbura O},
  year = {2026},
  journal = {European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  doi = {10.1016/j.ejso.2026.111731},
  url = {https://doi.org/10.1016/j.ejso.2026.111731}
}

RIS

TY  - JOUR
TI  - Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study.
AU  - Zambrano DA
AU  - Lintis A
AU  - Kefleyesus A
AU  - Taibi A
AU  - Eveno C
AU  - Pocard M
AU  - De Meeus G
AU  - Quénet F
AU  - Kepenekian V
AU  - Hübner M
AU  - Glehen O
AU  - Sgarbura O
PY  - 2026
JO  - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
DO  - 10.1016/j.ejso.2026.111731
UR  - https://doi.org/10.1016/j.ejso.2026.111731
ER  -

APA

DA, Z., A, L., A, K., A, T., C, E., M, P., G, D. M., F, Q., V, K., M, H., O, G., & O, S. (2026). Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. https://doi.org/10.1016/j.ejso.2026.111731

Source records

pubmed · retrieved 2026-09-26T19:41:57.607Z